Lilly cashes in on Loxo buyout with FDA approval for first-in-class cancer drug Retevmo

11th May 2020 Uncategorised 0

Eli Lilly has won its first approval for a pipeline drug coming out of the $8 billion acquisition of Loxo Oncology. The FDA approved Retevmo, or selpercatinib, as the first drug targeting RET-driven tumors. But Blueprint Medicines’ rival med is close behind.

More: Lilly cashes in on Loxo buyout with FDA approval for first-in-class cancer drug Retevmo
Source: fierce